FKBP52 dictates the dual role of p53 in hepatocellular carcinoma: Mutation-specific prognostic stratification and therapeutic implications.

Abstract excerpt

The lack of mutation-contextual therapeutic targets remains a major barrier in hepatocellular carcinoma (HCC) management. Immunohistochemical analysis of 341 human HCC specimens identified FK506-binding protein 52 (FKBP52) as a tumor grade-associated biomarker. In vitro, FKBP52 overexpression enhanced proliferation in p53-mutant liver cancer cells but suppressed it in p53-wild-type cells. Using two murine...

Topics

• Tacrolimus Binding Proteins
• Humans
• Carcinoma, Hepatocellular
• Liver Neoplasms
• Tumor Suppressor Protein p53
• Animals